These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19558313)

  • 21. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S
    Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
    Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
    Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strontium ranelate in the prevention of osteoporotic fractures.
    Reginster JY; Malaise O; Neuprez A; Bruyere O
    Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generalized cutaneous drug eruption due to strontium ranelate.
    Boada A; Carrascosa JM; Leal L; Ferrándiz C
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):321-2. PubMed ID: 18624862
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strontium: confusion and hallucinations. Do not use strontium.
    Prescrire Int; 2009 Oct; 18(103):216. PubMed ID: 19885972
    [No Abstract]   [Full Text] [Related]  

  • 29. Strontium ranelate lives to fight another day.
    Compston J
    Maturitas; 2014 Jun; 78(2):75-6. PubMed ID: 24780410
    [No Abstract]   [Full Text] [Related]  

  • 30. [Strontium ranelate for osteoporosis treatment].
    Kurth A
    Orthopade; 2014 Feb; 43(2):181. PubMed ID: 24693555
    [No Abstract]   [Full Text] [Related]  

  • 31. Interstitial granulomatous reaction to strontium ranelate.
    Groves C; McMenamin ME; Casey M; Barnes L
    Arch Dermatol; 2008 Feb; 144(2):268-9. PubMed ID: 18283194
    [No Abstract]   [Full Text] [Related]  

  • 32. Strontium as therapy for osteoporosis.
    Marie PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review.
    Boonen S
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S21-7. PubMed ID: 16735842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
    Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
    Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemorheological changes with strontium ranelate treatment do not seem to be related to its claimed prothrombotic effects.
    Ulger Z; Gurel EI; Halil M; Oozen G; Kalan I; Seringec N; Yavuz BB; Yesil Y; Cankurtaran M; Dikmenoglu N; Ariogul S
    Arch Gerontol Geriatr; 2012; 54(1):218-21. PubMed ID: 21167612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strontium ranelate: a physiological approach for optimizing bone formation and resorption.
    Marie PJ
    Bone; 2006 Feb; 38(2 Suppl 1):S10-4. PubMed ID: 16439191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
    Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
    Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
    Ortolani S; Vai S
    Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.